Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase III Trial Of Irofulven Vs. 5-Fluorouracil In Patients With Gemcitabine-Refractory Advanced Pancreatic Adenocarcinoma

NCT00033735 is registered in ClinicalTrials.gov with Eisai Inc. as lead sponsor.

NCT NCT00033735
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00033735 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase III Trial Of Irofulven Vs. 5-Fluorouracil In Patients With Gemcitabine-Refractory Advanced Pancreatic Adenocarcinoma
Lead sponsor
Eisai Inc.
Phase
Phase 3
Overall status
Completed
Start date
January 31, 2000
Completion date
Not reported
Enrollment
158 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

pancreatic cancer